Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Draadje OT, bijzaken & geleuter in de marge!
Volgen
aossa schreef op 14 augustus 2015 09:03 :
Uit de krant:
Bijna nergens is Europa groeide het aantal miljonairs harder dan in Nederland: een groei van 16,5 procent in 2013, tot 173 duizend.
Wat doe ik dan verkeerd;-)))
tonneke schreef op 14 augustus 2015 09:15 :
[...]Wat doe ik dan verkeerd;-)))
Niets want het zijn cijfers uit 2013 :-))
Curtis Carroll discovered the stock market in prison. Through friends and family on the outside, he invests from San Quentin State Prison in Northern California, and he's also an informal financial adviser to fellow inmates and correctional officers. Everyone in prison calls him Wall Street. "I couldn't believe that this kind of access to this type of money could be accessible to anybody. Everybody should do it. And it's legal!" he says. He pores over financial news: the Wall Street Journal, USA Today, Forbes. Business is like a soap opera, he says, and he's always trying to anticipate what will happen next. "I like to know what the CEO's doing," he says. "I like to know who's in trouble."www.npr.org/2015/08/14/431958714/inma...
Esperite verkrijgt patent voor ontwikkeling immuuntherapieen AMSTERDAM (Dow Jones)--Esperite nv (ESP.AE) heeft de volledige rechten gekregen voor het gebruik van een breed internationaal patent waarmee exosomen uit mesenchymale stamcellen (MSC) kunnen worden gebruikt in de ontwikkeling naar behandelingen tegen een breed aantal ontstekings- en auto-immuunziekten, zoals artritis, multiple sclerose, taaislijmziekte, type 1 diabetes, Graft- versus- host ziekte en hersen- en ruggenmergletsel. Exosomen zijn kleine blaasjes die worden uitgescheiden door cellen en hebben bepaalde biologische markers die meer informatie kunnen geven over de prognose voor diverse ziektes, inclusief het opsporen van kanker. Ze helpen ook om medicijnen preciezer toe te dienen, waardoor de dosering kan worden verlaagd en bijwerkingen worden tegen gegaan. De technologie waarvan Esperite nu het patent kan gebruiken, zorgt voor meer effectieve, veilige en betaalbare therapieen als een alternatief voor allogene stamceltherapieen, aldus het biotechbedrijf uit Zutphen. Door Marleen Groen; Dow Jones Nieuwsdienst; +31 20 5715 200; marleen.groen@wsj.com
De Galapagos-beleggers lopen de polonaise op het Galapagos-forum. Het aandeel noteert op een all time high en met +282,2% op het bord voor dit jaar is het bij uitstek het best presterende aandeel van het Damrak. En het feest is nog niet voorbij als het aan Jefferies ligt. Vandaag gaat het aandeel opnieuw hard omhoog en dit keer door een rapport van Jefferies. We bedanken onze forumleden, want dankzij deze beleggers kunnen we het rapport inlezen. Een bloemlezing uit het rapport.www.iex.nl/Column/162189/Jefferies-du...
Bedankt Flosz, had deze nog niet gelezen.
AbbVie hands United a record $350M payoff for a speedy FDA review voucher August 19, 2015 | By John Carroll The cost of a priority review voucher for the FDA keeps going up. AbbVie is forking over a record $350 million to acquire a voucher from United Therapeutics, giving them an option at shaving 4 months off the agency's standard 10-month review process. There's no immediate word from AbbVie ($ABBV) about which of their late-stage drugs will get the voucher, but at a cost of $87.5 million a month, the pharma company clearly has a potential blockbuster in mind. AbbVie and Roche are hustling the cancer drug venetoclax to the FDA for an accelerated review, with more late-stage therapies in the pipeline to pick from. The FDA is using the vouchers to help encourage R&D for pediatric and tropical diseases, handing out the vouchers for new approvals in those two fields. And every new deal brings a new record price tag. Sanofi and Regeneron drew considerable attention for their decision to pay the now bargain basement price of $67.5 million for a priority review voucher that allowed them to leapfrog Amgen on the first FDA approval for a PCSK9 cholesterol drug. Gilead scored a voucher for $125 million and then used it to accelerate a new HIV combo. And Sanofi fed the inflationary cycle with its $245 million voucher deal with Retrophin last May. AbbVie has good reason to demonstrate a sense of urgency. The company is heavily dependent on Humira for most of its income and has to diversity its product portfolio as quickly as possible In this case, United ($UTHR) gets to cash in on its approval of Unituxin, a new drug for rare cases of neuroblastoma. "We are very pleased to monetize our PPRV, and hope that this transaction will encourage others to join us in focusing development efforts on rare pediatric diseases," said Roger Jeffs, United Therapeutics' president and co-CEO, in a statement.twitter.com/johncfierce/status/633948...
'Tsipras kondigt vanavond nog ontslag aan' Het voortbestaan van de huidige Griekse regering hangt aan een zijden draadje. Volgens Griekse media zou premier Alexis Tsipras vanavond al zijn aftreden aankondigen. Nieuwe verkiezingen zouden dan voor 13 of 20 september kunnen zijn. Het nieuws over het mogelijke ontslag van Tsipras lekte uit enkele uren nadat Griekenland van de eurolanden een eerste schijf van 13 miljard euro uit het nieuwe hulpprogramma ter waarde van 86 miljard euro had ontvangen. Daarmee kon het land meteen de Europese Centrale Bank (ECB) en het Internationaal Monetair Fonds (IMF) terugbetalen. Maar net de voorwaarden die Griekenland moest slikken om dat geld te ontvangen, dreigen nu de huidige regering-Tsipras te doen vallen. De premier heeft het zwaar te verduren bij een deel van zijn partijgenoten. etc.
Ben erg benieuwd wat er na de verkiezingen in Griekenland gaat gebeuren...
NOVEL SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS tinyurl.com/naupkx5 FIELD OF THE INVENTION [0001] The present invention relates to the salt and crystalline forms of a compound according to Formula I, useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the salt of the invention inhibits JAK, a family of tyrosine kinases, and more particularly JAK1. The present invention also provides pharmaceutical compositions comprising the salt of the invention and methods for the prophylaxis and/or treatment of diseases including inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and/or disruption of cartilage homeostasis, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons by administering a salt of the invention according to Formula I. BACKGROUND OF THE INVENTION [0002] Current therapies for treating inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons, in particular rheumatoid arthritis, are far from satisfactory and there remains a need to identify new therapeutic agents that may be of use in their treatment. These conditions are chronic conditions which require long term therapy, and repeated intake of the drug. Long term treatment might be a heavy burden on the patient and the practitioner alike, since the patient might be or become intolerant to the drug, and furthermore high dosage, or high dosage frequency may result in uncomfortable side effects, and /or low patient compliance, where the patient may occasionally, deliberately or accidentally, miss a dose. The impact of non-adherence varies across chronic illnesses, and ranges from minimal to very significant (Ingersoll & Cohen, 2008). Therefore, there is a need to identify new agents to reinforce the arsenal of the practitioner, and compounds with low frequency dosage regimen to improve the life of the patients. [0003] Janus kinases (JAKs) are cytoplasmic tyrosine kinases that transduce cytokine signaling from membrane receptors to STAT transcription factors. Four JAK family members are described, JAK1, JAK2, JAK3 and TYK2. Upon binding of the cytokine to its receptor, JAK family members auto- and/or transphosphorylate each other, followed by phosphorylation of STATs that then migrate to the nucleus to modulate transcription. JAK-STAT intracellular signal transduction serves the interferons, most interleukins, as well as a variety of cytokines and endocrine factors such as EPO, TPO, GH, OSM, LIF, CNTF, GM-CSF and PRL (Vainchenker, Dusa, & Constantinescu, 2008). [0004] The combination of genetic models and small molecule JAK inhibitor research revealed the therapeutic potential of several JAKs. [0005] JAKl is a target in the immuno-inflammatory disease area. JAKl heterodimerizes with the other JAKs to transduce cytokine- driven pro-inflammatory signaling. Therefore, inhibition of JAKl is of interest for immuno-inflammatory diseases with pathology-associated cytokines that use JAKl signaling, such as IL-2, IL-6, IL-4, IL-5, IL-13, or IFNgamma, as well as for other diseases driven by JAK-mediated signal transduction. [0006] In the JAK family members' roles, some overlap exists, since most signaling pathways involve more than one JAK, however for some growth factors such as erythropoietin and thrombopoietin, only JAK2 is involved. [0007] JAK3 plays a major role in blocking immune function via transmission of signals generated by interleukin (IL)-2. [0008] On the other hand, TYK2 would appear to work in combination with JAK2 in order to transduce signaling of cytokines such as IL-12 and IL-23. [0009] The role of JAK enzymes has been mostly studied using mice where each of the JAK family members has been deleted. JAKl knockout mice exhibit a perinatal lethal phenotype and also have defective lymphoid development and function as a result of defective signaling by cytokines through JAKl . JAK2 deficiency results in embryonic lethality at day 12 as a result of a failure in definitive erythropoiesis. JAK3- deficient mice have severe combined immunodeficiency (SCID) phenotype but do not have non-immune defects (Verstovsek, 2009). [0010] As has been observed with pan JAK inhibitors, non-selective inhibition may be linked to side effects such as anemia , an increased rate of infections, lower neutrophil and lymphocyte counts, a decrease in haemoglobin, and elevated cholesterol levels (Dolgin, 2011). [0011] Therefore, the development of a selective JAK inhibitor would be beneficial in order to minimize such side effects. [0012] The degeneration of cartilage is the hallmark of various diseases, among which rheumatoid arthritis and osteoarthritis are the most prominent. Rheumatoid arthritis (RA) is a chronic joint degenerative disease, characterized by inflammation and destruction of the joint structures. When the disease is untreated, it can lead to substantial disability and pain due to loss of joint function and result in shortened life-expectancy. The aim of a RA therapy, therefore, is not only to slow down the disease but to attain remission in order to stop the joint destruction and improve quality of life. Besides the severity of the disease outcome, the high prevalence of RA (~ 0.8% of adults are affected worldwide) means a high socio-economic impact. (Smolen & Steiner, 2003) (O'Dell, 2004). JAKl is implicated in intracellular signal transduction for many cytokines and hormones. Pathologies associated with any of these cytokines and hormones can be ameliorated by JAKl inhibitors. Hence, several allergy, inflammation and autoimmune disorders might benefit from treatment with compounds described in this invention including rheumatoid arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, osteoarthritis, asthma, chronic obstructive pulmonary disease (COPD), tissue fibrosis, eosinophilic inflammation, eosophagitis, inflammatory bowel diseases (e.g. Crohn's disease, ulcerative colitis), transplant, graft-versus-host disease, psoriasis, myositis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and multiple sclerosis. (Kopf, Bachmann, & Marsland, 2010) [0013] Psoriasis is a disease that can affect the skin. The cause of psoriasis is not fully understood but it is believed that it is an immune mediated related disease linked to the release of cytokines, in particular TNFa, which causes inflammation and rapid reproduction of the skin cells. This hypothesis has been corroborated by the observation that immunosuppressant medication can clear psoriasis plaques. (Zenz, et al., 2005) Psoriasis can also cause inflammation of the joints, which is known as psoriatic arthritis. Between 10-30% of all people with psoriasis also have psoriatic arthritis. ((CHMP), 18 November 2004) Because of its chronic recurrent nature, psoriasis is a challenge to treat. It has recently been demonstrated that inhibition of JAK could result in successful improvement of the psoriatic condition (Punwani, et al., 2012). Meer via link.
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS tinyurl.com/pbumqbk
flosz schreef op 20 augustus 2015 17:46 :
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
tinyurl.com/pbumqbk Geweldige bijdrage flosz thx....(AB)
flosz schreef op 11 augustus 2015 20:19 :
[Modbreak IEX: Gelieve op uw taalgebruik te letten, bericht is bij dezen verwijderd.]
Beste mod., TERING is een ander woord voor TBC. Hier geplaatst met een link richting jaarverslag AERAS, die verzetten namelijk gigantisch veel werk om een oplossing te zoeken tegen TBC, TERING dus............. Probeer eens wat te lezen(ook @langetenenmetbordvoordekop): Annual Report 2014www.aeras.org/annualreport2014/
The FDA Is Basically Approving Everything. Here's The Data To Prove It Matthew Herper FORBES STAFF Remember when the FDA rejected drugs? We just got treated to a whole lot of drama this week as to whether Addyi, a drug to boost women’s libidos, would be approved. But based on the data, that approval was probably a foregone conclusion. As recently as 2008, companies filing applications to sell never-before-marketed drugs, which are referred to by the FDA as “new molecular entities,” faced rejection 66% of the time. Yet so far this year the FDA has rejected only three uses for new chemical entities, and approved 25, an approval rate of 89%. Those numbers come from a new analysis commissioned by Forbes from BioMedTracker, a division of publishing giant Informa that helps investors track events in the pharmaceutical industry. And if you dig into them, the drop is even sharper.www.forbes.com/sites/matthewherper/20...
flosz schreef op 20 augustus 2015 17:57 :
[...]
Beste mod., TERING is een ander woord voor TBC.
Klopt op de lagere school leerden we over TERING en over de PEST... Er was een jongen die zei dat zijn vader een TERINGLIJDER was en voor enkele maanden naar het sanatorium was om de herstellen.
@Chicken little Thanxs mate voor dat FDA artikel. Blijkt dat een van mijn holdings binnen 3 weken hoort of de BLA wordt geaccepteerd voor review. Gebaseerd op jou artikel ....... Overigens is de rubber stamp verwachting nog niet echt in de koers opgenomen, maar ja wat in het vat zit.
aossa schreef op 20 augustus 2015 18:10 :
[...]
Klopt op de lagere school leerden we over TERING en over de PEST...
Er was een jongen die zei dat zijn vader een TERINGLIJDER was en voor enkele maanden naar het sanatorium was om de herstellen.
Anderzijds ligt posten over je schooltijd vandaag erg gevoelig voor sommige leden. Mogelijke oorzaak : Voda is met vakantie
Bedrijf van vrouwelijke Viagra al na 1 dag overgenomen Soms gaat het wel heel erg snel. Gisteren kondigde Sprout Pharmaceuticals aan dat het van de FDA zijn lustpil voor vrouwen - merknaam: Addyi - op de Amerikaanse markt mag brengen. nog geen 24 uur later volgde het bericht dat Valeant het bedrijf overneemt. Valeant VRX -6,47% betaalt 1 miljard dollar cash, en zal een extraatje betalen als de 'vrouwelijke Viagra' bepaalde verkoopdrempels haalt. Voor Valeant tikt het rijtje overnames verder aan. Het miljardenbedrijf ontpopte zich tot dé deal maker in de farmasector.www.nasdaq.com/symbol/vrx
AbbVie Inc May Use Priority Voucher To Gain Lymphoma Lead Over Roche Holding Ltd. AbbVie paid $350 million to buy a priority review voucher yesterday. Here’s what analysts believe the voucher can be used for. On Wednesday, AbbVie Inc. (NYSE:ABBV) purchased a rare pediatric priority review voucher from United Therapeutics Corporation (NASDAQ:UTHR) for $350 million. United had received the voucher in March after the Food and Drug Administration (FDA) approved its drug, Unituxin, for the treatment of neuroblastoma. The voucher program aims at boosting development of neglected disease drugs. The voucher will help AbbVie to expedite the review process for one of its drugs, from a standard 10 months to 6 months. The company has not yet disclosed its plans for the voucher’s use, giving rise to speculations. Bloomberg Intelligence analysts Elizabeth Krutoholow and Grace Guo believe the company will use the voucher to file its blockbuster cancer drug Imbruvica, for expanded indication in relapsed or refractory follicular lymphoma.www.bidnessetc.com/50631-abbvie-inc-m...
flosz schreef op 20 augustus 2015 17:46 :
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
tinyurl.com/pbumqbk Wie is er thuis in deze materie? AbbVie heeft nog geen licentie maar vraagt een patent aan om filgotinib te gebruiken. Wat zijn dan op dat ogenblik de wettelijke consequenties omtrent het gebruik van figotinib?
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)